Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Star Imaging And Path LabBOM:544482 -2.22%21 FCF Margin % is 37.98% as of Mar. 2026, which is 207% above its 10-year median of 12.37. GuruFocus rates BOM:544482 with a GF Score™ of 21/100. Among 203 Medical Diagnostics & Research companies, Star Imaging And Path Lab ranks better than 82.27% on this metric.
The historical rank and industry rank for Star Imaging And Path Lab's FCF Margin % or its related term are showing as below:
BOM:544482'
s FCF Margin % Range Over the Past 10 Years
Min: -8.21 Med: 12.37 Max: 14.79
Current: 14.79
During the past 5 years, the highest FCF Margin % of Star Imaging And Path Lab was 14.79%. The lowest was -8.21%. And the median was 12.37%.
BOM:544482's FCF Margin % is ranked better than 82.27% of 203
companies
in the Medical Diagnostics & Research industry
Industry Median: -0.69
vs BOM:544482: 14.79
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BOM:544482 vs TMO, DHR, IDXX: FCF Margin % Comparison
For the Diagnostics & Research subindustry, Star Imaging And Path Lab's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Star Imaging And Path Lab FCF Margin % vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Star Imaging And Path Lab's FCF Margin % distribution charts can be found below:
* The bar in red indicates where Star Imaging And Path Lab's FCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Star Imaging And Path Lab (BOM:544482) has a FCF Margin % of 37.98% as of Mar. 2026. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Star Imaging And Path Lab and its competitors. This is 207% above median its historical median of 12.37. According to the industry distribution chart, Star Imaging And Path Lab ranks #36 out of 203 companies in the Medical Diagnostics & Research industry, placing it in the top 17.7%.
Is Star Imaging And Path Lab's FCF Margin % too high?
Star Imaging And Path Lab's current FCF Margin % of 37.98% is 207% above median its 10-year median of 12.37. Based on the distribution chart, Star Imaging And Path Lab ranks #36 out of 203 companies in the Medical Diagnostics & Research industry, which is in the top quartile — a strong position relative to peers. Overall, Star Imaging And Path Lab has a GF Score™ of 21/100, reflecting its overall financial health beyond just this single metric.
How does Star Imaging And Path Lab's FCF Margin % compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Star Imaging And Path Lab ranks #36 out of 203 companies for FCF Margin %. This places Star Imaging And Path Lab in the top 18% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Margin % for a Medical Diagnostics & Research company?
A good FCF Margin % depends on the Medical Diagnostics & Research industry context. However, FCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Margin % mean?
A high FCF Margin % can signal that a stock is expensive relative to its fundamentals. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Star Imaging And Path Lab and its competitors. Star Imaging And Path Lab's current FCF Margin % is 37.98%, which is 207% above median its own 10-year median of 12.37. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Star Imaging And Path Lab stock overvalued right now?
Star Imaging And Path Lab (BOM:544482) has a current FCF Margin % of 37.98%. The current FCF Margin % is 37.98%, which is 207% above median its 10-year median of 12.37. Star Imaging And Path Lab's overall GF Score™ is 21/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Margin % calculated?
FCF Margin % is calculated from a company's financial statements. For Star Imaging And Path Lab (BOM:544482), the current FCF Margin % is 37.98% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Star Imaging And Path Lab Ltd operates a diagnostic testing network, NABL accredited, delivering pathology, radiology, Cardiology, and Neurology services in Delhi and Uttar Pradesh. It offers a comprehensive range of diagnostic imaging services and clinical laboratory tests, including both routine and specialized studies and profiles. These services are essential for the prediction, early detection, diagnostic screening, confirmation, and monitoring of diseases. The company's diagnostic imaging and radiology services encompass X-rays, computed tomography (CT) scans, magnetic resonance imaging (MRI) scans, ultrasounds, bone mineral densitometry, and mammography.
21GF Score
Get the complete analysis for BOM:544482
FCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:544482 has been successfully added to your 
